Is Vericel Corp. overvalued or undervalued?

As of 19 September 2025, the valuation grade for Vericel Corp. has moved from fair to very attractive, indicating a shift towards a more favorable assessment. Based on the available metrics, the company appears to be undervalued. Key ratios include a P/E ratio of 732, a Price to Book Value of 7.38, and an EV to EBITDA of 517.61, which suggest significant discrepancies when compared to peers.
In comparison to its peers, Vericel Corp. has a notably high P/E ratio of 235.86, while Harmony Biosciences Holdings, Inc. has a P/E of 11.40, and Amphastar Pharmaceuticals, Inc. shows a P/E of 11.49. This stark contrast reinforces the notion that Vericel may be undervalued relative to its performance metrics. Additionally, while Vericel's stock has underperformed the S&P 500 over the past year with a return of -31.69% compared to the index's 16.64%, it has shown a positive return of 33.94% over the last three years, suggesting potential for recovery and growth.